Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
92 hedge funds and large institutions have $577M invested in Adaptimmune Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 7 closing their positions.
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
27% more call options, than puts
Call options by funds: $2.49M | Put options by funds: $1.96M
21% more capital invested
Capital invested by funds: $476M → $577M (+$102M)
12% more funds holding
Funds holding: 82 → 92 (+10)
0% less ownership
Funds ownership: 71.49% → 71.49% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$11.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.97M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$5.06M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.48M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.89M |
| 2 |
Morgan Stanley
New York
|
-$8.76M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$8.62M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$5.63M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$4.34M |
ADAP Hedge Fund Activity: Q3 2021 in Review
92 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2021, worth a combined $577M — up 21% from $476M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ADAP positions and 7 closed out — a net gain of 11 holders — while 31 added to existing stakes and 22 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $11.4M. The largest seller was Point72 Asset Management, cutting an estimated $8.89M.
- 92 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2021, up from 82 in Q2 2021.
- Funds reported $577M of Adaptimmune Therapeutics stock for Q3 2021, up 21% quarter-over-quarter.
- 18 funds opened new Adaptimmune Therapeutics positions in Q3 2021 and 7 closed out, a net change of +11 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2021 was Citadel Advisors, an estimated $11.4M added.
- The largest Adaptimmune Therapeutics seller in Q3 2021 was Point72 Asset Management, an estimated $8.89M sold.
Based on aggregated 13F filings for Q3 2021.